Search Results

There are 15586 results for: content related to: The Bruton tyrosine kinase ( BTK ) inhibitor PCI -32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma ( DLBCL ) and mantle cell lymphoma ( MCL ) cells sensitive or resistant to bortezomib

  1. You have full text access to this OnlineOpen article
    Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

    Pharmacology Research & Perspectives

    Volume 3, Issue 4, August 2015, Jan de Jong, Donna Skee, Joe Murphy, Juthamas Sukbuntherng, Peter Hellemans, Johan Smit, Ronald de Vries, Juhui James Jiao, Jan Snoeys and Erik Mannaert

    Version of Record online : 24 JUN 2015, DOI: 10.1002/prp2.156

  2. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies

    Clinical Pharmacology & Therapeutics

    Volume 97, Issue 5, May 2015, Pages: 455–468, Y Wang, LL Zhang, RE Champlin and ML Wang

    Version of Record online : 3 APR 2015, DOI: 10.1002/cpt.85

  3. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

    British Journal of Haematology

    Volume 170, Issue 4, August 2015, Pages: 445–456, Shuang Q. Zhang, Sonali M. Smith, Shuang Y. Zhang and Yue Lynn Wang

    Version of Record online : 9 APR 2015, DOI: 10.1111/bjh.13427

  4. You have free access to this content
    In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1

    British Journal of Pharmacology

    Volume 171, Issue 24, December 2014, Pages: 5845–5857, Hui Zhang, Atish Patel, Shao-Lin Ma, Xiao Jie Li, Yun-Kai Zhang, Pei-Qi Yang, Rishil J Kathawala, Yi-Jun Wang, Nagaraju Anreddy, Li-Wu Fu and Zhe-Sheng Chen

    Version of Record online : 24 NOV 2014, DOI: 10.1111/bph.12889

  5. You have free access to this content
    The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

    British Journal of Haematology

    Volume 166, Issue 2, July 2014, Pages: 177–188, Mariela Sivina, Robert J. Kreitman, Evgeny Arons, Farhad Ravandi and Jan A. Burger

    Version of Record online : 2 APR 2014, DOI: 10.1111/bjh.12867

  6. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas

    Clinical Pharmacology & Therapeutics

    Volume 97, Issue 5, May 2015, Pages: 469–477, L Alinari, C Quinion and KA Blum

    Version of Record online : 20 JAN 2015, DOI: 10.1002/cpt.65

  7. You have free access to this content
    Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells

    British Journal of Haematology

    Volume 166, Issue 6, September 2014, Pages: 849–861, Jiao Ma, Pin Lu, Ailin Guo, Shuhua Cheng, Hongliang Zong, Peter Martin, Morton Coleman and Y. Lynn Wang

    Version of Record online : 24 JUN 2014, DOI: 10.1111/bjh.12974

  8. Targeting protein kinase C in mantle cell lymphoma

    British Journal of Haematology

    Volume 173, Issue 3, May 2016, Pages: 394–403, Hilka Rauert-Wunderlich, Martina Rudelius, German Ott and Andreas Rosenwald

    Version of Record online : 23 FEB 2016, DOI: 10.1111/bjh.13973

  9. You have full text access to this OnlineOpen article
    Targets for Ibrutinib Beyond B Cell Malignancies

    Scandinavian Journal of Immunology

    Volume 82, Issue 3, September 2015, Pages: 208–217, A. Berglöf, A. Hamasy, S. Meinke, M. Palma, A. Krstic, R. Månsson, E. Kimby, A. Österborg and C. I. E. Smith

    Version of Record online : 18 AUG 2015, DOI: 10.1111/sji.12333

  10. You have free access to this content
    Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma

    International Journal of Cancer

    Volume 136, Issue 12, 15 June 2015, Pages: 2761–2774, Sophie Bernard, Damien Danglade, Laura Gardano, Christelle Laguillier, Gregory Lazarian, Claudine Roger, Catherine Thieblemont, Jacek Marzec, John Gribben, Florence Cymbalista, Nadine Varin-Blank, Dominique Ledoux and Fanny Baran-Marszak

    Version of Record online : 3 DEC 2014, DOI: 10.1002/ijc.29326

  11. You have free access to this content
    The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells

    British Journal of Haematology

    Volume 170, Issue 1, July 2015, Pages: 134–138, Yang Cao, Guang Yang, Zachary R. Hunter, Xia Liu, Lian Xu, Jie Chen, Nickolas Tsakmaklis, Evdoxia Hatjiharissi, Sandra Kanan, Matthew S. Davids, Jorge J. Castillo and Steven P. Treon

    Version of Record online : 12 JAN 2015, DOI: 10.1111/bjh.13278

  12. The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 3, March 2014, Pages: 303–314, Valkal Bhatt, Linh Alejandro, Angela Michael and Alex Ganetsky

    Version of Record online : 12 DEC 2013, DOI: 10.1002/phar.1366

  13. Recent advances in therapy of chronic lymphocytic leukaemia

    British Journal of Haematology

    David J. M. Routledge and Adrian J. C. Bloor

    Version of Record online : 13 JUN 2016, DOI: 10.1111/bjh.14184

  14. You have free access to this content
    Poster Presentations

    Hematological Oncology

    Volume 33, Issue S1, June 2015, Pages: 181–243,

    Version of Record online : 9 JUN 2015, DOI: 10.1002/hon.2228

  15. You have free access to this content
    Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors

    American Journal of Hematology

    Volume 90, Issue 7, July 2015, Pages: 657–664, Anthony Mato, Shekeab Jauhari and Stephen J. Schuster

    Version of Record online : 28 MAY 2015, DOI: 10.1002/ajh.24021

  16. Ibrutinib, Obinutuzumab, Idelalisib, and Beyond: Review of Novel and Evolving Therapies for Chronic Lymphocytic Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 12, December 2014, Pages: 1298–1316, Clement Chung and Rosetta Lee

    Version of Record online : 30 OCT 2014, DOI: 10.1002/phar.1509

  17. You have full text access to this OnlineOpen article
    Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

    Annals of the New York Academy of Sciences

    Volume 1358, Issue 1, November 2015, Pages: 82–94, Urte Gayko, Mann Fung, Fong Clow, Steven Sun, Elizabeth Faust, Samiyeh Price, Danelle James, Margaret Doyle, Samina Bari and Sen Hong Zhuang

    Version of Record online : 8 SEP 2015, DOI: 10.1111/nyas.12878

  18. Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults

    British Journal of Clinical Pharmacology

    Volume 81, Issue 2, February 2016, Pages: 235–245, Ronald de Vries, Johan W. Smit, Peter Hellemans, James Jiao, Joseph Murphy, Donna Skee, Jan Snoeys, Juthamas Sukbuntherng, Maarten Vliegen, Loeckie de Zwart, Erik Mannaert and Jan de Jong

    Version of Record online : 15 JAN 2016, DOI: 10.1111/bcp.12787

  19. You have free access to this content
    Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

    British Journal of Haematology

    Volume 163, Issue 4, November 2013, Pages: 436–443, Amin Aalipour and Ranjana H. Advani

    Version of Record online : 24 SEP 2013, DOI: 10.1111/bjh.12573

  20. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modelling

    Clinical Pharmacology & Therapeutics

    Accepted manuscript online: 1 JUL 2016, L. de Zwart, J. Snoeys, J. de Jong, J. Sukbuntherng, E. Mannaert and M. Monshouwer

    DOI: 10.1002/cpt.419